| Popis: |
OBJECTIVE There is evidence showing that GH and IGF-I have specific receptors in the heart and that these hormones are able to promote cardiac remodelling and inotropism. It has been reported that patients with dilated cardiomyopathy (DCM) benefit from treatment with rhGH showing a striking increase in cardiac contractility. However, until now, the activity of GH/IGF-I axis in DCM has never been clearly assessed. PATIENTS To clarify this point, we enrolled 39 patients with idiopathic or post-ischaemic DCM (36 M/3 F; age (mean ± S.D.) 55.3 ± 9.0 years; BMI: 25.3 ± 3.2 kg/m2; New York Heart Association class (NYHA) I/2, II/19, III/15, IV/3) and 42 age-matched controls (CS, 38 M/4 F; age 56.0 ± 7.8 years; BMI: 24.9 ± 1.5 kg/m2). DCM patients were characterized by a left-ventricular diastolic diameter of 73.8 ± 8.3 mm, a shortening fraction of 15.9 ± 6.4% and a left ventricular ejection fraction of 25.1 ± 8.7%. In all subjects clinical and biochemical indices of renal and hepatic function as well as nutritional parameters were in the normal range. MEASUREMENTS In both groups we studied: a) IGF-I levels in basal conditions and after administration of low rhGH doses for 4 days (5.0 or 10.0 μ/kg/day × 4 days); b) the acute GH-response to GHRH (1.0 μ/kg i.v.) or hexarelin (HEX, 2.0 μ/kg i.v.), a peptidyl GH secretagogue (GHRP); c) mean GH concentration (mGHc) over 10 h sampling (every 20 min) from 2200 h to 0800 h. RESULTS Basal IGF-I levels in DCM were lower (P = 0.000039) than in CS (135.2 ± 46.8 vs. 193.7 ± 63.7 μ/l), whereas, basal IGFBP-3 and GHBP2 levels in DCM and CS were similar (2.5 ± 1.3 vs. 2.6 ± 0.5 mg/l and 25.3 ± 3.6 vs. 28.3 ± 5.0%; P = 0.95 and P = 0.085, respectively). After 4 days of 5.0 μ/kg/day rhGH administration, IGF-I levels in DCM (215.4 ± 82.0 μ/l; P = 0.0023 vs. baseline) remained lower (P = 0.027) than those in CS (280.0 ± 80.7 μ/l; P = 0.000080 vs. baseline). After 10.0 μ/kg/day for 4 days, IGF-I levels in DCM (297.2 ± 109.2 μ/l; P = 0.0033 vs. baseline) were similar (P = 0.76) to those in CS (310.9 ± 81.7 μ/l; P = 0.000060 vs. baseline). The GH response to GHRH in DCM was lower (P = 0.0022) than that in CS (hAUC0 →120: 192.0 ± 177.3 vs. 345.3 ± 191.1 μ/l/h) whereas that to HEX in DCM and CS was similar (611.0 ± 437.5 vs. 535.4 ± 302.8 μ/l/h; P = 0.95). Within the DCM group, basal and rhGH-stimulated IGF-Ievels as wel as the GH response to GHRH or HEX were not different among NYHA classes and did not show any correlation with ECHO parameters. The mGHc in DCM (1.0 ± 0.5 μ/l) was similar (P = 0.57) to that in CS (0.9=0.7 μ/l). CONCLUSIONS Our present data demonstrate that in dilated cardiomyopathy patients with severe left ventricular dysfunction basal IGF-I levels are reduced whereas the IGF-I response to low rhGH doses is preserved. These findings suggest a normal peripheral GH sensitivity in dilated cardiomyopathy. On the other hand, though nocturnal mean GH concentration in dilated cardiomyopathy patients is similar to that in normal subjects, the somatotroph responsiveness to GHRH, but not that to hexarelin, is reduced. Thus, subtle alterations in the activity of GH/IGF-I axis are present in dilated cardiomyopathy. |
Plný text